---
title: "Oncolytic Virotherapy: Evolving from Cold-to-Hot to a Foundational Immuno‑Oncology Platform"
id: "nature-reviews-clinical-oncology-0-beyond-cold-to-hot-oncolytic-virotherapy-as-the-next-cornerstone-of-immuno"
canonical_url: "https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-beyond-cold-to-hot-oncolytic-virotherapy-as-the-next-cornerstone-of-immuno"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Nature Reviews Clinical Oncology"
source_url: "https://www.nature.com/articles/s41571-026-01198-z"
published_at: "2026-09-03T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Oncolytic Virotherapy: Evolving from Cold-to-Hot to a Foundational Immuno‑Oncology Platform
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-beyond-cold-to-hot-oncolytic-virotherapy-as-the-next-cornerstone-of-immuno
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Nature Reviews Clinical Oncology
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41571-026-01198-z)
- **Published At:** 2026-09-03T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The Perspective argues that **oncolytic virotherapy** has progressed from simple tumour lysis to a sophisticated system for intratumoural immune reprogramming, and that the common “cold-to-hot” framing is incomplete. - A shared limitation of **immune checkpoint inhibitors (ICIs)** and early-generation **oncolytic viruses (OVs)** is dependence on pre-existing tumour-specific T cells (TSTs), which imposes an immunological ceiling on antitumour responses because these agents have limited capacity to create new TSTs de novo. - Next-generation, payload-engineered OVs act as **antigen-agnostic in situ cancer vaccines** by infecting tumours intratumourally, causing immunogenic cell death and releasing a broad set of tumour antigens together with pathogen- or damage-associated molecular pattern adjuvants, promoting de novo T cell priming against patient-specific neoantigens. - The authors delineate four development pillars for next-generation OVs: (1) intratumoural vaccination as immunological ignition, with early clinical signals including T cell clonotype broadening, abscopal regression and survival benefit in ICI‑refractory patients; (2) optimized payload-driven immune priming to hyperactivate antigen-presenting cells; (3) revised efficacy evaluation and endpoints that capture delayed and systemic immune-mediated tumour control; and (4) using OVs as a foundational immuno‑oncology platform under a **triple-A** framework (admission, availability and activation of TSTs). - According to the Perspective, payload-engineered OVs uniquely satisfy all three prerequisites for productive antitumour immunity simultaneously, supporting an “OV‑prime, ICI‑amplify” clinical strategy. - The authors emphasize that OVs are systemic immune‑reprogramming platforms delivered locally, not merely local therapies with incidental systemic effects. - Figures in the article illustrate OV-mediated in situ vaccination and the **triple-A** gate model for antitumour immunity; the full text and detailed data are behind subscription access. - The article synthesizes current conceptual advances and early clinical observations to propose strategic directions for OV development and assessment in immuno‑oncology.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41571-026-01198-z#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Reviews Clinical Oncology](https://media.springernature.com/full/nature-cms/uploads/product/nrclinonc/header-6cacb5c22900eb4634682a8eae5b788c.svg) ](https://www.nature.com/nrclinonc) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41571-026-01198-z) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nrclinonc/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nrclinonc/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nrclinonc/news-and-comment) * [ Current issue ](https://www.nature.com/nrclinonc/current-issue) * [ Collections ](https://www.nature.com/nrclinonc/collections) * [Follow us on Facebook ](https://www.facebook.com/NatureReviews) * [Follow us on X ](https://twitter.com/NatRevClinOncol) * [ Subscribe ](https://www.nature.com/nrclinonc/subscribe) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41571) * [ RSS feed ](https://www.nature.com/nrclinonc.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nrclinonc/aims) * [ Journal Information ](https://www.nature.com/nrclinonc/journal-information) * [ Editorial policies ](https://www.nature.com/nrclinonc/editorial-policies) * [ About the Editors ](https://www.nature.com/nrclinonc/editors) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nrclinonc/reviews-cross-journal-editorial-team) * [ Journal Credits ](https://www.nature.com/nrclinonc/journal-credits) * [ Editorial input and checks ](https://www.nature.com/nrclinonc/editorial-input-and-checks) * [ Editorial Values Statement ](https://www.nature.com/nrclinonc/editorial-values-statement) * [ Journal Metrics ](https://www.nature.com/nrclinonc/journal-impact) * [ Publishing model ](https://www.nature.com/nrclinonc/publishing-model) * [ Conferences ](https://www.nature.com/nrclinonc/conferences) * [ Web Feeds ](https://www.nature.com/nrclinonc/web-feeds) * [ Contact ](https://www.nature.com/nrclinonc/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ For Authors ](https://www.nature.com/nrclinonc/for-authors) * [ For Referees ](https://www.nature.com/nrclinonc/for-referees) * [Submit manuscript ](https://mts-nrclinonc.nature.com/cgi-bin/main.plex) * [ Subscribe ](https://www.nature.com/nrclinonc/subscribe) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41571) * [ RSS feed ](https://www.nature.com/nrclinonc.rss) 1. [nature](https://www.nature.com/) 2. [nature reviews clinical oncology](https://www.nature.com/nrclinonc) 3. [perspectives](https://www.nature.com/nrclinonc/articles?type=perspective) 4. article * Perspective * Published: 03 September 2026 # Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology * [William Jia](https://www.nature.com/articles/s41571-026-01198-z#auth-William-Jia-Aff1) [ORCID: orcid.org/0000-0002-2755-6821](https://orcid.org/0000-0002-2755-6821)[1](https://www.nature.com/articles/s41571-026-01198-z#Aff1), * [Ronghua Zhao](https://www.nature.com/articles/s41571-026-01198-z#auth-Ronghua-Zhao-Aff1)[1](https://www.nature.com/articles/s41571-026-01198-z#Aff1), * [Howard L. Kaufman](https://www.nature.com/articles/s41571-026-01198-z#auth-Howard_L_-Kaufman-Aff2-Aff3) [ORCID: orcid.org/0000-0003-1131-004X](https://orcid.org/0000-0003-1131-004X)[2](https://www.nature.com/articles/s41571-026-01198-z#Aff2),[3](https://www.nature.com/articles/s41571-026-01198-z#Aff3) & * … * [Robert L. Martuza](https://www.nature.com/articles/s41571-026-01198-z#auth-Robert_L_-Martuza-Aff4-Aff5) [ORCID: orcid.org/0000-0003-1901-0113](https://orcid.org/0000-0003-1901-0113)[4](https://www.nature.com/articles/s41571-026-01198-z#Aff4),[5](https://www.nature.com/articles/s41571-026-01198-z#Aff5) Show authors [_Nature Reviews Clinical Oncology_](https://www.nature.com/nrclinonc) (2026) [Cite this article](https://www.nature.com/articles/s41571-026-01198-z#citeas) [ Save article ](https://www.nature.com/articles/s41571-026-01198-z/save-research?_csrf=uYAxs0CYAA6oSKl1FOIyP44dGfFz5hkD) [ View saved research ](https://www.nature.com/saved-research) ## Abstract Oncolytic virotherapy has evolved from a platform predicated on lysis of cancer cells into a sophisticated system for intratumoural immune reprogramming; the prevailing ‘cold-to-hot’ paradigm captures only part of this potential. A fundamental limitation shared by immune checkpoint inhibitors (ICIs) and early-generation oncolytic viruses (OVs) is a reliance on pre-existing tumour-specific T cells (TSTs), which presents an immunological ceiling that constrains antitumour activity — given that these agents have a limited capacity to generate TSTs de novo. Next-generation OVs overcome this constraint by functioning as agents for antigen-agnostic in situ cancer vaccination: intratumoural infection triggers immunogenic cell death, releasing potentially the full cancer proteome under pathogen-associated and/or damage-associated molecular pattern adjuvant conditions, thereby driving T cell priming against patient-specific neoantigens. In this Perspective, we delineate four pillars for the development of next-generation OVs. First, intratumoural vaccination as immunological ignition, with initial clinical data demonstrating T cell clonotype broadening, abscopal tumour regression and survival benefit in patients with ICI-refractory disease. Second, optimized payload-driven immune priming to hyperactivate antigen-presenting cells. Third, revised efficacy evaluation and end points using response criteria as well as novel biological correlates that better capture delayed and abscopal immune-mediated tumour control. Fourth, OV as the foundational immuno-oncology platform: according to the ‘triple-A’ framework encompassing admission, availability and activation of TSTs, next-generation, payload-engineered OVs uniquely satisfy all prerequisites for antitumour immunity simultaneously, with evidence from clinical trials of such agents supporting an ‘OV-prime, ICI-amplify’ strategy. Notably, OVs are systemic immune-reprogramming platforms that are delivered locally, not local therapies with incidental systemic effects. This is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01198-z) ## Access options [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01198-z) Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 € / 30 days cancel any time [Learn more](https://shop.nature.com/products/plus/?region=ROW) Subscribe to this journal Receive 12 print issues and online access 176,64 € per year only 14,72 € per issue [Learn more](https://www.nature.com/nrclinonc/subscribe) Buy this article * Purchase on SpringerLink * Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout ### Additional access options: * [Log in](https://idp.nature.com/authorize/natureuser?client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01198-z) * [Learn about institutional subscriptions](https://www.springernature.com/gp/librarians/licensing/license-options) * [Read our FAQs](https://support.nature.com/en/support/home) * [Contact customer support](https://www.springernature.com/gp/contact) **Fig. 1: Oncolytic viruses for in situ vaccination.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41571-026-01198-z/MediaObjects/41571_2026_1198_Fig1_HTML.png) **Fig. 2: Triple-A gate model for productive antitumour immunity across therapeutic modalities.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41571-026-01198-z/MediaObjects/41571_2026_1198_Fig2_HTML.png) ### Explore related subjects Discover the latest articles and news in related subjects. * [Oncology](https://www.nature.com/subjects/oncology) * [Tumour immunology](https://www.nature.com/subjects/tumour-immunology) ## References 1. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. _N. Engl. J. Med._ **363** , 711–723 (2010). [Article](https://doi.org/10.1056%2Fnejmoa1003466) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXhtVCrtrbN) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20525992) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549297) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Improved%20survival%20with%20ipilimumab%20in%20patients%20with%20metastatic%20melanoma&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2Fnejmoa1003466&volume=363&pages=711-723&publication_year=2010&author=Hodi%2CFS) 2. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. _N. Engl. J. Med._ **372** , 2521–2532 (2015). [Article](https://doi.org/10.1056%2Fnejmoa1503093) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtFyrsbrF) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25891173) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Pembrolizumab%20versus%20ipilimumab%20in%20advanced%20melanoma&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2Fnejmoa1503093&volume=372&pages=2521-2532&publication_year=2015&author=Robert%2CC) 3. Sharma, P. et al. The future of immune checkpoint therapy. _Science_ **348** , 56–61 (2015). [Article](https://doi.org/10.1126%2Fscience.aaa8172) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXls1Wmurg%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25838373) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=The%20future%20of%20immune%20checkpoint%20therapy&journal=Science&doi=10.1126%2Fscience.aaa8172&volume=348&pages=56-61&publication_year=2015&author=Sharma%2CP) 4. Haslam, A. et al. How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis. _Int. J. Cancer_ **156** , 2352–2359 (2025). [Article](https://doi.org/10.1002%2Fijc.35347) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2MXhtVWhsL3F) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=39887747) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=How%20many%20people%20in%20the%20US%20are%20eligible%20for%20and%20respond%20to%20checkpoint%20inhibitors%3A%20an%20empirical%20analysis&journal=Int.%20J.%20Cancer&doi=10.1002%2Fijc.35347&volume=156&pages=2352-2359&publication_year=2025&author=Haslam%2CA) 5. Garg, P. et al. Next-generation immunotherapy: advancing clinical applications in cancer treatment. _J. Clin. Med._ **13** , 6537 (2024). [Article](https://doi.org/10.3390%2Fjcm13216537) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2cXisFWkurfE) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=39518676) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11546714) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Next-generation%20immunotherapy%3A%20advancing%20clinical%20applications%20in%20cancer%20treatment&journal=J.%20Clin.%20Med.&doi=10.3390%2Fjcm13216537&volume=13&publication_year=2024&author=Garg%2CP) 6. Xiong, A. et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. _Lancet_ **405** , 839–849 (2025). [Article](https://doi.org/10.1016%2Fs0140-6736%2824%2902722-3) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2MXptVCjtL0%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=40057343) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ivonescimab%20versus%20pembrolizumab%20for%20PD-L1-positive%20non-small%20cell%20lung%20cancer%20%28HARMONi-2%29%3A%20a%20randomised%2C%20double-blind%2C%20phase%203%20study%20in%20China&journal=Lancet&doi=10.1016%2Fs0140-6736%2824%2902722-3&volume=405&pages=839-849&publication_year=2025&author=Xiong%2CA) 7. Gao, X. et al. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial. _Lancet Oncol._ **24** , 1134–1146 (2023). [Article](https://doi.org/10.1016%2Fs1470-2045%2823%2900411-4) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXitFWisb7J) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37797632) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Safety%20and%20antitumour%20activity%20of%20cadonilimab%2C%20an%20anti-PD-1%2FCTLA-4%20bispecific%20antibody%2C%20for%20patients%20with%20advanced%20solid%20tumours%20%28COMPASSION-03%29%3A%20a%20multicentre%2C%20open-label%2C%20phase%201b%2F2%20trial&journal=Lancet%20Oncol.&doi=10.1016%2Fs1470-2045%2823%2900411-4&volume=24&pages=1134-1146&publication_year=2023&author=Gao%2CX) 8. Zeidan, A. M. et al. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. _Lancet Haematol._ **11** , e38–e50 (2024). [Article](https://doi.org/10.1016%2FS2352-3026%2823%2900333-2) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXisFCrt7rK) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38065203) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Sabatolimab%20plus%20hypomethylating%20agents%20in%20previously%20untreated%20patients%20with%20higher-risk%20myelodysplastic%20syndromes%20%28STIMULUS-MDS1%29%3A%20a%20randomised%2C%20double-blind%2C%20placebo-controlled%2C%20phase%202%20trial&journal=Lancet%20Haematol.&doi=10.1016%2FS2352-3026%2823%2900333-2&volume=11&pages=e38-e50&publication_year=2024&author=Zeidan%2CAM) 9. Peters, S. et al. SKYSCRAPER-01: a phase III, randomized trial of tiragolumab + atezolizumab versus placebo + atezolizumab in patients with previously-untreated PD-L1-high, locally advanced unresectable/metastatic NSCLC [abstract]. _Cancer Res._ **85** , CT051 (2025). [Article](https://doi.org/10.1158%2F1538-7445.AM2025-CT051) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=SKYSCRAPER-01%3A%20a%20phase%20III%2C%20randomized%20trial%20of%20tiragolumab%20%2B%20atezolizumab%20versus%20placebo%20%2B%20atezolizumab%20in%20patients%20with%20previously-untreated%20PD-L1-high%2C%20locally%20advanced%20unresectable%2Fmetastatic%20NSCLC%20%5Babstract%5D&journal=Cancer%20Res.&doi=10.1158%2F1538-7445.AM2025-CT051&volume=85&publication_year=2025&author=Peters%2CS) 10. Laguna, J. C. et al. Rethinking strategies in SCLC: lessons learned from tiragolumab in the SKYSCRAPER-02 study. _Med_ **5** , 281–284 (2024). [Article](https://doi.org/10.1016%2Fj.medj.2024.02.001) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2cXpsFGjsLY%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38614072) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Rethinking%20strategies%20in%20SCLC%3A%20lessons%20learned%20from%20tiragolumab%20in%20the%20SKYSCRAPER-02%20study&journal=Med&doi=10.1016%2Fj.medj.2024.02.001&volume=5&pages=281-284&publication_year=2024&author=Laguna%2CJC) 11. Regeneron Pharmaceuticals. Regeneron provides update on phase 3 trial of fianlimab (LAG-3 inhibitor) combination in first-line unresectable or metastatic melanoma. _GlobeNewswire_ [https://www.globenewswire.com/news-release/2026/05/16/3296192/0/en/ Regeneron-Provides-Update-on-Phase-3-Trial-of-Fianlimab-LAG-3-Inhibitor -Combination-in-First-Line-Unresectable-or-Metastatic-Melanoma.html](https://www.globenewswire.com/news-release/2026/05/16/3296192/0/en/Regeneron-Provides-Update-on-Phase-3-Trial-of-Fianlimab-LAG-3-Inhibitor-Combination-in-First-Line-Unresectable-or-Metastatic-Melanoma.html) (2026). 12. Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. _N. Engl. J. Med._ **386** , 24–34 (2022). [Article](https://doi.org/10.1056%2Fnejmoa2109970) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XhtFaltr4%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34986285) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844513) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Relatlimab%20and%20nivolumab%20versus%20nivolumab%20in%20untreated%20advanced%20melanoma&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2Fnejmoa2109970&volume=386&pages=24-34&publication_year=2022&author=Tawbi%2CHA) 13. Chen, D. S. et al. Elements of cancer immunity and the cancer–immune set point. _Nature_ **541** , 321–330 (2017). [Article](https://doi.org/10.1038%2Fnature21349) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXht1Oksr8%3D)
## Related Clinical Research

- [Translational modelling questions receptor‑occupancy‑based dosing for pembrolizumab (PD‑1 inhibito](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-translational-modelling-challenges-receptor-occupancy-based-dosing-of-pd-1.md)
- [PD-L1 expression and survival in unresectable or recurrent gastric cancer treated with first-line](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-pd-l1-expression-and-survival-in-unresectable-recurrent-gastric-cancer-treated.md)
- [Challenging FDA-Approved Cancer Drug Dosages: A Patient and Research Perspective](https://medichelpline.com/clinical-feed/kff-health-news-2-how-much-of-a-cancer-drug-is-too-much-patients-researchers-challenge-fda.md)
- [Safety profiles of PD-1/CTLA-4 and PD-1/VEGF bispecific antibodies in NSCLC: pooled systematic rev](https://medichelpline.com/clinical-feed/pubmed-42554769.md) (DOI: 10.1186/s43046-026-00387-2)
- [Chemotherapy and Immunotherapy Dosing in Congenital Achondroplasia: Case Report and Review](https://medichelpline.com/clinical-feed/pubmed-42545505.md) (DOI: 10.1007/s00280-026-04932-7)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.